I-Mab Biopharma Co., Ltd. - IMAB Company Short-Term Debt

I-Mab Inc. (IMAB) - corporate logo

The price characteristics of I-Mab (IMAB) on the GURU.Markets platform, where the indicator stands at 0.00, reflect a company developing a broad spectrum of anti-tumor agents. The sale of local stakes and the optimization of its capital structure have provided the financial stability necessary to conduct global trials. Meanwhile, the business relies on costly temperature control during drug transportation, which is critical for maintaining their efficacy.

IMAB (I-Mab) Company Short-Term Debts history from 07/04/2022 to 10/30/2025

I-Mab Biopharma Co., Ltd. - analytical breakdowns and key metrics (IMAB)

- price and consensus price forecast:
Stock Price I-Mab Inc.|IMAB - Average Forecast Price
- market capitalization data:
Market Value I-Mab Biopharma|IMAB - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share I-Mab|IMAB - Book Capitalization|Market Value to Book Value Ratio i-mabbiopharma.com|IMAB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio I-Mab|IMAB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity I-Mab Inc.|IMAB - Company Cumulative Debt|Debt to Book Capitalization Ratio I-Mab Biopharma|IMAB - Company Long-Term Indebtedness|Company Short-Term Debts I-Mab
Fundamental company valuation:I-Mab
Signature product of I-Mab Inc.

Short-term debt reflects the total sum of all financial obligations with a maturity of less than one year. Analyzing aggregate short-term liabilities allows for an assessment of the issuer's current liquidity and solvency. This metric measures the risk of cash flow gaps when servicing accounts payable. For I-Mab (IMAB), this indicator is critical due to a high dependency on external CRO and CMO contractors. Stable debt management ensures uninterrupted funding for the global outsourcing of antibody development.

Competitors of I-Mab (IMAB)

INCY (Incyte) - Company Short-Term Debts|HCM: Short-Term Debt|Company Short-Term Debt Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc (DAWN) - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts INBX|Company Short-Term Debt Fennec Pharmaceuticals Inc. (FENC)|Company Short-Term Debt herontx.com HRTX|Company Current Liabilities Nuvectis|Coherus BioSciences - Company Short-Term Loans and Borrowings|CRBP (Corbus Pharmaceuticals) - Company Short-Term Debt|CRDF: Short-Term Debt|Company Short-Term Debt BeyondSpring|BioAtla (BCAB) - Company Short-Term Indebtedness|Company Short-Term Debts LIXT|Company Current Liabilities CTXR|Cellectar Biosciences - Company Short-Term Debt|Short-Term Debt BLRX (biolinerx.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA (Kazia) - Company Short-Term Debt|SLXN - Short-Term Debt|Company Short-Term Debts NCNA (nucana.com)|Short-Term Indebtedness chimerix.com|Company Current Liabilities CYCC (Cyclacel)|Short-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Current Liabilities|Company Short-Term Loans and Borrowings Kintara Pharma KTRA|Company Current Liabilities Oncternal Therapeutics (ONCT)|Amount of Current Liabilities portagebiotech.com PRTG